FGFR2 overexpression or amplification has become an area of interest for the development of new targeted-based treatment. This article focuses on the genom
Ifinatamab deruxtecan has demonstrated antitumor activity as second-line or later therapy in patients with ES-SCLC.
The University of Texas MD Anderson Cancer Center and Rice University today announced the launch of the Center for Operations Research in Cancer, a joint…
Join the AACR for its Special Conference in Cancer Research: RNAs as Drivers, Targets, and Therapeutics in Cancer, November 14-17, 2024.
Researchers may have uncovered a metabolic pathway that could lead to the development of predictive biomarkers for immune checkpoint inhibitors in NSCLC, according to findings…
FDA will hold the first National Hispanic/Latino Family Cancer Awareness Week to increase cancer awareness within the Hispanic/Latino population.
The Environmental Services team ensures infection prevention and patient satisfaction
Developing and Retaining a Robust and Diverse Cancer Workforce: Challenges and Opportunities Across the National Cancer Program
Precision oncology endeavors to tailor therapies based on individual patient and tumor characteristics. This rapidly evolving field has transformed cancer treatment across all age groups.…
Laurie H. Glimcher, MD, announced today that she will step down as Dana-Farber Cancer Institute President and CEO on October 1, 2024, and will assume…
Nina, Diffuse Large B-Cell Lymphoma Survivor My journey with lymphoma began three days before New York City was on lockdown for the 2020 COVID pandemic…
